Status:
COMPLETED
The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.
Lead Sponsor:
The University of Texas Health Science Center, Houston
Conditions:
Bony Metastases From Castrate Refractory Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
To describe the changes seen on bone scan and correlate them with changes in relative chemical biomarkers, patient's functional status and level of pain.
Eligibility Criteria
Inclusion
- Prostate cancer patients scheduled for treatment with Radium-223.
Exclusion
- Patients not completing their treatment regimen for any reason
Key Trial Info
Start Date :
February 11 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 7 2017
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT03368989
Start Date
February 11 2014
End Date
February 7 2017
Last Update
June 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030